Gri bio reports 6-week interim lung function data in ongoing phase 2a study in idiopathic pulmonary fibrosis (“ipf”)

No decline in lung function observed at 6-week interim analysis  builds upon positive safety and biomarker data
GRI Ratings Summary
GRI Quant Ranking